# ESMO-THE CHRISTIE PRECEPTORSHIP PROGRAMME

# LUNG CANCER

Multidisciplinary management, standards of care and future perspectives

**Manchester, United Kingdom**
**10-12 March 2027**

## CO-CHAIRS

Raffaele Califano, United Kingdom
Pilar Garrido López, Spain

## SPEAKERS

Helen Adderley, United Kingdom
Paul Baas, Netherlands
Haval Balata, United Kingdom
Claire Barker, United Kingdom
Paolo Bironzo, Italy
Richard Booton, United Kingdom
Clara Chan, United Kingdom
Christopher Craig, United Kingdom
Simon Ekman, Sweden
Corinne Faivre-Finn, United Kingdom
Igor Gomez-Randulfe, United Kingdom
Keith M. Kerr, United Kingdom
Jennifer A. King, United Kingdom
Rohit Kochhar, United Kingdom
Cécile Le Péchoux, France
Thomas Newsom-Davis, United Kingdom
Luis Paz-Ares, Spain
David Planchard, France
Cecilia Pompili, United Kingdom
Christina H. Ruhlmann, Denmark
Suresh Senan, Netherlands
Yvonne Summers, United Kingdom
Paul Taylor, United Kingdom
Willemijn Theelen, Netherlands
Fiona Thistlethwaite, United Kingdom
Giulia Veronesi, Italy

## LEARNING OBJECTIVES

- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early-stage NSCLC and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and SCLC
- To learn about the role of supportive and palliative care for thoracic malignancies

## ACCREDITATION

The programme of this event has been accredited with **16 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

## Wednesday, 10 March 2027

| | | |
|---|---|---|
| **08:15-09:15<br>60'** | **Registration** | |
| **09:15-09:25<br>10'** | **Welcome and introduction** | **Raffaele Califano, UK** |
| **09:25-12:25<br>150'** | **SESSION 1<br>Screening and diagnostics for lung cancer** | **Co-Chairs:<br>Raffaele Califano, UK<br>Keith M. Kerr, UK** |
| 30' | Lung cancer screening | Haval Balata, UK |
| 30' | EBUS TBNA in diagnosis/staging of lung cancer | Richard Booton, UK |
| 10:25-10:55 | Coffee break | |
| 30' | Role of pathologist in diagnosis and mutation analysis of lung cancer | Keith M. Kerr, UK |
| 30' | PET/CT in staging of lung cancer | Rohit Kochhar, UK |
| 30' | Diagnosis and management of malignant pleural effusion | Christopher Craig, UK |
| 12:25-13:25 | Lunch | |
| **13:25-16:25<br>150'** | **SESSION 2<br>Radical treatment of early stage NSCLC** | **Co-Chairs:<br>Cécile Le Péchoux, FR<br>Suresh Senan, NL** |
| 30' | Stereotactic ablative RT for early-stage NSCLC | Suresh Senan, NL |
| 30' | Adjuvant radiotherapy for completely resected early-stage NSCLC | Cécile Le Péchoux, FR |
| 30' | Adjuvant systemic therapies for resected early-stage NSCLC | Paul Taylor, UK |
| 14:55-15:25 | Coffee break | |
| 30' | Surgery for early-stage NSCLC | Giulia Veronesi, IT |
| 30' | Participants clinical case discussion (3x10') | Faculty |
| **16:25-17:25<br>60'** | **SESSION 3<br>Locally advanced NSCLC** | **Co-Chairs:<br>Paolo Bironzo, IT<br>Cecilia Pompili, UK** |
| 30' | Combined modality treatment for unresectable NSCLC | Clara Chan, UK |
| 30' | Role of surgery for N2 disease | Cecilia Pompili, UK |
| **17:25-17:35<br>10'** | **Conclusion of day 1** | **Raffaele Califano, UK** |

## **Thursday**, 11 March 2027

| **09:00-09:30<br>30'** | **SESSION 2<br>Radical treatment of early stage NSCLC – Cont.** | **Chair:<br>Pilar Garrido-López, ES** |
|---|---|---|
| 30' | Perioperative immunotherapy-based strategies for resectable NSCLC co-chair Pilar Garrido | Yvonne Summers, UK |

| **09:30-12:30<br>150'** | **SESSION 4<br>Advanced NSCLC** | **Co-Chairs:<br>Pilar Garrido-López, ES<br>Luis Paz-Ares, ES** |
|---|---|---|
| 30' | First-line immune-checkpoint blockade for advanced NSCLC | Luis Paz-Ares, ES |
| 30' | First-line chemotherapy for advanced NSCLC | David Planchard, FR |
| 10:30-11:00 | Coffee break | |
| 30' | Second-line treatment for advanced NSCLC | Paolo Bironzo, IT |
| 30' | Treatment of EGFR mutant advanced NSCLC | Raffaele Califano, UK |
| 30' | Treatment of ALK and ROS1 positive advanced NSCLC | Thomas Newsom-Davis, UK |
| 12:30-13:30 | Lunch | |

| **13:30-15:00<br>90'** | **SESSION 5<br>Palliative treatment of lung cancer and mesothelioma** | **Co-Chairs:<br>Simon Ekman, SE<br>Pilar Garrido-López, ES** |
|---|---|---|
| 30' | Treatment of advanced NSCLC harboring KRAS mutation and MET aberrations | Helen Adderley, UK |
| 30' | Beyond EGFR, ALK, ROS1 and KRAS: Novel molecularly driven targeted therapies in NSCLC | Simon Ekman, SE |
| 30' | Treatment of oligometastatic NSCLC | Willemijn Theelen, NL |
| 15:00-15:30 | Coffee break | |

| **15:30-17:00<br>90'** | **SESSION 5 - cont.<br>Palliative treatment of lung cancer and mesothelioma** | **Co-Chairs:<br>Paul Baas, NL<br>Christina H. Ruhlmann, DK** |
|---|---|---|
| 30' | Systemic treatment of mesothelioma | Paul Baas, NL |
| 30' | Radical treatment of brain metastases: The importance of a neuro-oncology multi-disciplinary approach | Jennifer A. King, UK |
| 30' | Supportive and palliative care in lung cancer | Christina H. Ruhlmann, DK |

| **17:00-17:30<br>30'** | **SESSION 6<br>SCLC** | **Chair:<br>Raffaele Califano, UK** |
|---|---|---|
| 30' | First-line chemo-immunotherapy for SCLC | Pilar Garrido López, ES |

| **17:30-17:40<br>10'** | **Conclusion of day 2** | **Raffaele Califano, UK<br>Pilar Garrido López, ES** |
|---|---|---|
| 19:00 | Welcome drink | |
| 19:30 | Dinner | |

## **Friday**, 12 March 2027

| **09:00-10:30**<br>**90'** | **SESSION 6 – cont.**<br>**SCLC** | **Co-Chairs:**<br>**Igor Gomez-Randulfe, UK**<br>**Pilar Garrido López, ES** |
|---|---|---|
| 30' | Participants clinical case discussion (3x10') | Faculty |
| 30' | Second-line therapies for SCLC | Igor Randulfe, UK |
| 30' | Treatment of limited stage SCLC | Corinne Faivre-Finn, UK |
| 10:30-11:00 | Coffee break | |
| **11:00-12:30**<br>**90'** | **SESSION 6 - cont.**<br>**SCLC** | **Chair:**<br>**Raffaele Califano, UK** |
| 30' | Novel targeted therapies in SCLC | Igor Gomez-Randulfe, UK |
| 30' | Prophylactic cranial irradiation and role of thoracic RT for extensive stage SCLC | Claire Barker, UK |
| 30' | Next generation therapeutics for lung cancer | Fiona Thistlethwaite, UK |
| **12:30-12:35**<br>**5'** | **Conclusion and farewell** | **Raffaele Califano, UK** |
| 12:35-13:35 | Lunch | |

**Note**: Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion